PEG-MGF: how it got to PCAC

Origin

PEG-MGF is a polyethylene-glycol-conjugated form of “Mechano Growth Factor” (MGF), a name used in the muscle-physiology literature for a synthetic peptide derived from the C-terminal E-domain of the IGF-1 Ec splice variant. The 2011 study by Kandalla and colleagues at the Université Pierre et Marie Curie and University College London characterized a 24-amino-acid synthetic MGF-E peptide in human muscle satellite cell cultures and tied the molecule explicitly to the alternatively spliced IGF-1 Ec transcript PMID 21354439. The PEG conjugation is intended to extend serum half-life of the small peptide; PEGylation of IGF-1-family peptides has been investigated as a pharmacokinetic strategy for related, longer molecules in the IGF-1 family.

Research history

Kandalla et al. (2011) reported that synthetic MGF-E activated proliferation and fusion of human muscle satellite cells in vitro, with effects most pronounced in cells from younger donors and diminished in cells from older donors. The authors framed the molecule as a candidate intervention for age-related sarcopenia rather than as a clinically validated therapy.

The principal indexed clinical pharmacokinetic data on PEGylation of an IGF-1-family peptide come from a 2017 first-in-man phase 1 study by Kletzl and colleagues at Hoffmann-La Roche, who tested a pegylated recombinant human IGF-I (RO5046013) in 62 healthy volunteers and reported a half-life of 140-200 hours for the pegylated form, compared with the short half-life of unmodified IGF-I PMID 28110155. That study is not a study of PEG-MGF itself — it is a study of PEGylated full-length IGF-1 — but it is the closest-published pharmacokinetic precedent for the PEGylation strategy applied to PEG-MGF and has been cited in regulatory and scientific discussion of the MGF preparation.

A PubMed search for “PEG-MGF” itself returns no indexed records as of May 2026; the literature on the PEGylated MGF preparation circulating in compounding-nomination contexts is therefore extrapolated from the synthetic MGF-E peptide work cited above and from the broader IGF-1 PEGylation literature.

Regulatory journey

PEG-MGF has no FDA-approved drug application. The full-length recombinant IGF-1 product mecasermin is approved for primary IGF-1 deficiency in pediatric patients, but mecasermin is a different molecule from MGF-E and is not the substance under PCAC review. Compounding pharmacies that wish to use PEG-MGF as a bulk drug substance must rely on the section 503A framework, which permits compounding from substances that appear on FDA’s 503A bulks list or that are the subject of an approved drug application.

The agency’s program page describes the bulks-list workflow and the interim three-category framework: Category 1 (eligible pending rulemaking), Category 2 (significant safety concerns, not eligible pending further evaluation), and Category 3 (insufficient information) (FDA — Bulk Drug Substances Used in Compounding). A range of peptide bulk-drug nominations, including PEG-MGF and other IGF-1-related preparations, were placed in Category 2 pending advisory-committee review under FDA’s “may present significant safety risks” notice (FDA Category 2 notice).

FDA scheduled PEG-MGF for the Pharmacy Compounding Advisory Committee meeting at the end of February 2027. PCAC will review the nomination materials, the agency’s safety analysis, and any public comment, and will recommend whether the substance should be added to the 503A bulks list.

What’s at stake

PEG-MGF sits at the intersection of three FDA concerns: peptide nominations as a class; IGF-1-family biology, where the agency has historically scrutinized growth-promoting agents for cancer-risk, glycemic, and World Anti-Doping Agency considerations; and PEGylation as a half-life-extension strategy applied to an unapproved active. The February 2027 briefing materials are expected to address all three. This page will be updated when those materials are released.